6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia
- PMID: 11243403
- DOI: 10.1038/sj.leu.2401986
6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia
Abstract
Through inhibition of purine de novo synthesis and enhancement of 6-mercaptopurine (6MP) bioavailability high-dose methotrexate (HDM) may increase the incorporation into DNA of 6-thioguanine nucleotides (6TGN), the cytoxic metabolites of 6MP. Thus, coadministration of 6MP could increase myelotoxicity following HDM. Twenty-one children with standard risk (SR) and 25 with intermediate risk (IR) acute lymphoblastic leukemia (ALL) were studied. During consolidation therapy they received either three courses of HDM at 2 week intervals without concurrent oral 6MP (SR-ALL) or four courses of HDM given at 2 week intervals with 25 mg/m2 of oral 6MP daily (IR-ALL). During the first year of maintenance with oral 6MP (75 mg/m2/day) and oral MTX (20 mg/m2/week) they all received five courses of HDM at 8 week intervals. In all cases, HDM consisted of 5,000 mg of MTX/m2 given over 24 h with intraspinal MTX and leucovorin rescue. Erythrocyte levels of 6TGN (E-6TGN) and methotrexate (E-MTX) were, on average, measured every second week during maintenance therapy. When SR consolidation (6MP: 0 mg), IR consolidation (6MP: 25 mg/m2), and SR/IR maintenance therapy (6MP: 75 mg/m2) were compared, white cell and absolute neutrophil count (ANC) nadir, lymphocyte count nadir, thrombocyte count nadir, and hemoglobin nadir after HDM decreased significantly with increasing doses of oral 6MP. Three percent of the HDM courses given without oral 6MP (SR consolidation) were followed by an ANC nadir <0.5 x 10(9)/l compared to 50% of the HDM courses given during SR/IR maintenance therapy. Similarly, only 13% of the HDM courses given as SR-ALL consolidation induced a thrombocyte count nadir <100 x 10(9)/l compared to 58% of the HDM courses given during maintenance therapy. The best-fit model to predict the ANC nadir following HDM during maintenance therapy included the dose of 6MP prior to HDM (beta = -0.017, P= 0.001), the average ANC level during maintenance therapy (beta = 0.82, P = 0.004), and E-6TGN (beta = -0.0029, P= 0.02). The best-fit model to predict the thrombocyte nadir following HDM during maintenance therapy included only mPLATE (beta = 0.0057, P = 0.046). In conclusion, the study indicates that reductions of the dose of concurrently given oral 6MP could be one way of reducing the risk of significant myelotoxicity following HDM during maintenance therapy of childhood ALL.
Similar articles
-
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17. doi: 10.1097/MPH.0000000000000206. J Pediatr Hematol Oncol. 2014. PMID: 24936744 Free PMC article. Review.
-
Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.Cancer Chemother Pharmacol. 2015 May;75(5):1089-93. doi: 10.1007/s00280-015-2717-8. Epub 2015 Mar 19. Cancer Chemother Pharmacol. 2015. PMID: 25788208
-
Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia.Leukemia. 2003 Jul;17(7):1344-8. doi: 10.1038/sj.leu.2402990. Leukemia. 2003. PMID: 12835723
-
Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.Pediatr Hematol Oncol. 1996 Sep-Oct;13(5):433-41. doi: 10.3109/08880019609030855. Pediatr Hematol Oncol. 1996. PMID: 10897815
-
The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).Gen Pharmacol. 1999 Oct;33(4):341-6. doi: 10.1016/s0306-3623(99)00022-1. Gen Pharmacol. 1999. PMID: 10523073 Review.
Cited by
-
Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.Asian Pac J Cancer Prev. 2021 Jul 1;22(7):2025-2031. doi: 10.31557/APJCP.2021.22.7.2025. Asian Pac J Cancer Prev. 2021. PMID: 34319023 Free PMC article.
-
Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study.Indian J Hematol Blood Transfus. 2020 Jul;36(3):498-504. doi: 10.1007/s12288-019-01245-z. Epub 2020 Jan 2. Indian J Hematol Blood Transfus. 2020. PMID: 32647424 Free PMC article.
-
The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate.Int J Pediatr Adolesc Med. 2016 Dec;3(4):162-168. doi: 10.1016/j.ijpam.2016.08.008. Epub 2016 Sep 12. Int J Pediatr Adolesc Med. 2016. PMID: 30805487 Free PMC article.
-
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66. doi: 10.1007/s00280-014-2613-7. Epub 2014 Oct 28. Cancer Chemother Pharmacol. 2015. PMID: 25347948 Free PMC article.
-
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17. doi: 10.1097/MPH.0000000000000206. J Pediatr Hematol Oncol. 2014. PMID: 24936744 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials